$RGBP The company is currently developing small mo
Post# of 53474
Posted On: 09/20/2016 1:59:51 PM
$RGBP The company is currently developing small molecule drugs that target NR2F6 and either inhibit production of these factors or, in other cases, stimulate their production. The goal is to have a series of compounds that can modulate the immune system up or down. http://finance.yahoo.com/news/regen-biopharma...00084.html $ACTL $WRAP
(0)
(0)Scroll down for more posts ▼